Kamada stock launches two biosimilars as portfolio reaches four

Published on 10/08/2026 at 03:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kamada stock last traded at USD 7.89 on October 7, 2026, while its biosimilar portfolio reached four products. Four analysts hold a Buy consensus with a USD 13.50 target.

KMDA, IL0010941198, Illustration mit AI erstellt.

Kamada Ltd. (ISIN IL0010941198) was last at USD 7.89 on Nasdaq on October 7, 2026, down 2.71 percent from the prior close. The company had announced two Israeli biosimilar launches one day earlier, giving investors a new commercial growth marker.

Two products expand the portfolio

According to StockTitan on October 6, 2026, Kamada launched Ustekinumab-Kamada, a biosimilar to Stelara, and Enoxaparin-Kamada, a biosimilar to Clexane, in Israel. Both products were approved and launched as interchangeable with their reference biologics.

The launches lifted Kamada's commercial biosimilar portfolio to four products, alongside Bevacizumab-Kamada and Pegfilgrastim-Kamada. The company expects at least two additional biosimilars to become commercially available during 2027, while its long-term plan calls for at least 12 marketed products by 2030.

Sales projections raise the stakes

The new portfolio is still small relative to Kamada's established plasma-derived business. The October 6 filing projects biosimilar sales of USD 4 million in 2026, USD 10 million in 2028 and USD 20 million to USD 25 million in annual revenue by 2030, with products licensed from six international biosimilar companies.

The latest reported quarter provides a profitability baseline. MarketBeat reported that second-quarter 2026 adjusted earnings per share reached USD 0.16 versus a USD 0.11 consensus, while revenue was USD 54.92 million against USD 50.84 million expected. The comparison matters because the biosimilar strategy must add growth without weakening the company's existing earnings profile.

Analysts see higher value

Investing.com reported on October 7, 2026, that Stifel reiterated a Buy rating and a USD 11.00 price target after the launches. The report also said the company plans at least two further biosimilars in 2027 and expects the portfolio to reach 12 products by 2030.

According to MarketBeat on September 28, 2026, four analysts carried a Buy rating, with an average target of USD 13.50. That target lies 71.1 percent above the USD 7.89 Nasdaq price, although Sidoti had reduced its fiscal 2026 earnings estimate to USD 0.42 from USD 0.46.

Stock stays below yearly high

Kamada stock was last at USD 7.89 on Nasdaq on October 7, 2026, with a session range of USD 7.84 to USD 7.96. The 52-week range was USD 6.55 to USD 9.35, placing the latest price USD 1.46 below the yearly high.